| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Pre-clinical data readout example | SAB-142 Type 1 Diabetes (T1D) | Pre-clinical | 22% SAB-142 is SAB Biotherapeutics’ lead asset targeting type 1 diabetes (T1D), a fully human anti-thymocyte immunoglobulin (hIgG) designed to delay the onset and progression of this autoimmune disease by modulating the immune response against pancreatic beta cells. As a first-in-class therapy, SAB-142 is positioned as a novel fully human alternative to rabbit anti-thymocyte globulin (ATG), aiming to preserve the same disease-modifying concept while potentially improving redosing and tolerability. The program has progressed beyond pre-clinical stages into human studies, with a first-in-human Phase 1 trial reported in Australia in October 2023. Currently, a Phase 2b study, named SAFEGUARD (NCT07187531), is underway, featuring a randomized, placebo-controlled, investigator- and participant-blinded design involving 159 participants across three arms: high-dose SAB-142, low-dose SAB-142, and placebo. The T1D market presents a significant opportunity, estimated at $30-35 billion globally. This figure reflects the ongoing chronic use of insulin, glucose-monitoring technologies, and the large population currently receiving treatment. However, a critical unmet need persists, as there remains no approved disease-modifying therapy that reliably prevents the onset of T1D or preserves beta-cell function at scale. The absence of such therapies underscores the importance of demonstrating a clear clinical benefit over existing insulin-centric care and other immune-modulating approaches currently in development. SAB-142 is still in the early clinical stage, having only reached first-in-human and early Phase 2 development. Consequently, there is no established proof of efficacy, and the primary uncertainty revolves around whether the biologic activity observed will translate into clinically meaningful beta-cell preservation. Additionally, the program carries inherent risks associated with safety and immunosuppression. As an anti-thymocyte immunoglobulin, there are central risks related to infection, immune suppression, and infusion-related toxicities. The trial protocol explicitly excludes patients with recent serious infections and significant liver disease, indicating a cautious approach to managing these risks. Furthermore, while rabbit ATG has demonstrated biologic and clinical activity in T1D, it does not guarantee that SAB-142 will achieve a superior benefit-risk profile or reproducible efficacy in the target population. Upcoming catalysts for SAB-142 include enrollment and interim progress updates from the Phase 2b SAFEGUARD study, with timing yet to be disclosed. Additionally, top-line efficacy and safety data from the Phase 2b study are anticipated by December 31, 2028. Further clinical updates from the SAB-142-101 early T1D study are also expected, although specific timelines remain undisclosed. In terms of regulatory designations, there is no public evidence of Fast Track, Orphan Drug, Breakthrough Therapy, Priority Review, or Accelerated Approval for SAB-142 in the context of T1D, suggesting that these designations should be treated as false in the absence of public notice. Given the current evidence, a probability of approval (PoA) of 22.0% is justified. This figure reflects a higher likelihood than that of an unvalidated preclinical asset, as the mechanism has class support and the program has entered controlled human testing. However, it remains significantly lower than late-phase assets due to the lack of human efficacy proof and the high bar for safety and durable disease modification that SAB-142 must clear. Overall, while the potential for SAB-142 exists within a substantial market, the path forward is fraught with challenges that must be navigated carefully. Read More | Biologics | Endocrine System | ||
Pre-clinical data readout example | SAB-142 Type 1 Diabetes (T1D) | Pre-clinical | 22% SAB-142 is SAB Biotherapeutics’ lead asset targeting type 1 diabetes (T1D), a fully human anti-thymocyte immunoglobulin (hIgG) designed to delay the onset and progression of this autoimmune disease by modulating the immune response against pancreatic beta cells. As a first-in-class therapy, SAB-142 is positioned as a novel fully human alternative to rabbit anti-thymocyte globulin (ATG), aiming to preserve the same disease-modifying concept while potentially improving redosing and tolerability. The program has progressed beyond pre-clinical stages into human studies, with a first-in-human Phase 1 trial reported in Australia in October 2023. Currently, a Phase 2b study, named SAFEGUARD (NCT07187531), is underway, featuring a randomized, placebo-controlled, investigator- and participant-blinded design involving 159 participants across three arms: high-dose SAB-142, low-dose SAB-142, and placebo. The T1D market presents a significant opportunity, estimated at $30-35 billion globally. This figure reflects the ongoing chronic use of insulin, glucose-monitoring technologies, and the large population currently receiving treatment. However, a critical unmet need persists, as there remains no approved disease-modifying therapy that reliably prevents the onset of T1D or preserves beta-cell function at scale. The absence of such therapies underscores the importance of demonstrating a clear clinical benefit over existing insulin-centric care and other immune-modulating approaches currently in development. SAB-142 is still in the early clinical stage, having only reached first-in-human and early Phase 2 development. Consequently, there is no established proof of efficacy, and the primary uncertainty revolves around whether the biologic activity observed will translate into clinically meaningful beta-cell preservation. Additionally, the program carries inherent risks associated with safety and immunosuppression. As an anti-thymocyte immunoglobulin, there are central risks related to infection, immune suppression, and infusion-related toxicities. The trial protocol explicitly excludes patients with recent serious infections and significant liver disease, indicating a cautious approach to managing these risks. Furthermore, while rabbit ATG has demonstrated biologic and clinical activity in T1D, it does not guarantee that SAB-142 will achieve a superior benefit-risk profile or reproducible efficacy in the target population. Upcoming catalysts for SAB-142 include enrollment and interim progress updates from the Phase 2b SAFEGUARD study, with timing yet to be disclosed. Additionally, top-line efficacy and safety data from the Phase 2b study are anticipated by December 31, 2028. Further clinical updates from the SAB-142-101 early T1D study are also expected, although specific timelines remain undisclosed. In terms of regulatory designations, there is no public evidence of Fast Track, Orphan Drug, Breakthrough Therapy, Priority Review, or Accelerated Approval for SAB-142 in the context of T1D, suggesting that these designations should be treated as false in the absence of public notice. Given the current evidence, a probability of approval (PoA) of 22.0% is justified. This figure reflects a higher likelihood than that of an unvalidated preclinical asset, as the mechanism has class support and the program has entered controlled human testing. However, it remains significantly lower than late-phase assets due to the lack of human efficacy proof and the high bar for safety and durable disease modification that SAB-142 must clear. Overall, while the potential for SAB-142 exists within a substantial market, the path forward is fraught with challenges that must be navigated carefully. Read More | Biologics | Endocrine System | ||
Pre-clinical data readout example | SAB-142 Type 1 Diabetes (T1D) | Pre-clinical | 22% SAB-142 is SAB Biotherapeutics’ lead asset targeting type 1 diabetes (T1D), a fully human anti-thymocyte immunoglobulin (hIgG) designed to delay the onset and progression of this autoimmune disease by modulating the immune response against pancreatic beta cells. As a first-in-class therapy, SAB-142 is positioned as a novel fully human alternative to rabbit anti-thymocyte globulin (ATG), aiming to preserve the same disease-modifying concept while potentially improving redosing and tolerability. The program has progressed beyond pre-clinical stages into human studies, with a first-in-human Phase 1 trial reported in Australia in October 2023. Currently, a Phase 2b study, named SAFEGUARD (NCT07187531), is underway, featuring a randomized, placebo-controlled, investigator- and participant-blinded design involving 159 participants across three arms: high-dose SAB-142, low-dose SAB-142, and placebo. The T1D market presents a significant opportunity, estimated at $30-35 billion globally. This figure reflects the ongoing chronic use of insulin, glucose-monitoring technologies, and the large population currently receiving treatment. However, a critical unmet need persists, as there remains no approved disease-modifying therapy that reliably prevents the onset of T1D or preserves beta-cell function at scale. The absence of such therapies underscores the importance of demonstrating a clear clinical benefit over existing insulin-centric care and other immune-modulating approaches currently in development. SAB-142 is still in the early clinical stage, having only reached first-in-human and early Phase 2 development. Consequently, there is no established proof of efficacy, and the primary uncertainty revolves around whether the biologic activity observed will translate into clinically meaningful beta-cell preservation. Additionally, the program carries inherent risks associated with safety and immunosuppression. As an anti-thymocyte immunoglobulin, there are central risks related to infection, immune suppression, and infusion-related toxicities. The trial protocol explicitly excludes patients with recent serious infections and significant liver disease, indicating a cautious approach to managing these risks. Furthermore, while rabbit ATG has demonstrated biologic and clinical activity in T1D, it does not guarantee that SAB-142 will achieve a superior benefit-risk profile or reproducible efficacy in the target population. Upcoming catalysts for SAB-142 include enrollment and interim progress updates from the Phase 2b SAFEGUARD study, with timing yet to be disclosed. Additionally, top-line efficacy and safety data from the Phase 2b study are anticipated by December 31, 2028. Further clinical updates from the SAB-142-101 early T1D study are also expected, although specific timelines remain undisclosed. In terms of regulatory designations, there is no public evidence of Fast Track, Orphan Drug, Breakthrough Therapy, Priority Review, or Accelerated Approval for SAB-142 in the context of T1D, suggesting that these designations should be treated as false in the absence of public notice. Given the current evidence, a probability of approval (PoA) of 22.0% is justified. This figure reflects a higher likelihood than that of an unvalidated preclinical asset, as the mechanism has class support and the program has entered controlled human testing. However, it remains significantly lower than late-phase assets due to the lack of human efficacy proof and the high bar for safety and durable disease modification that SAB-142 must clear. Overall, while the potential for SAB-142 exists within a substantial market, the path forward is fraught with challenges that must be navigated carefully. Read More | Biologics | Endocrine System |
Recent Updates
Recently added Catalysts
SAB Biotherapeutics, Inc.$3.38
0 (0%)
C 51Pipeline Score Fair Value Biotech · Commercial
Market Cap
298.21 M
EPS
-1.00
P/E Ratio
-
Value Trade
1.11 M
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
13.40 M
Operating CF
-14.27 M
Total Assets
248.47 M
Total Liabilities
21.22 M
Equity
227.25 M
D/E Ratio
12,345
1.56 %
Week
1.3 %
1 Month
1.3 %
3 Month
1.3 %
6 Month
-96.03 %
5 Year
-96.18 %
All Time
Cash Data
Cash Position
107.39 M
Monthly Burn
4.76 M
Runway
21.9 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
158.61 K
52 Week Range
1.60 - 6.60
% held by Insiders
25.35 %
% held by Institutions
76.6 %
Enterprise Value
196.99 M
Total Shares
50.94 M
Short %
4.81 %
Float Shares
47.12 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C51
Pipeline Score $801M
Pipeline ValueFair Value
Valuation Signal5
Drugs Scored2.7x
rNPV / MCap Top 73%
Micro Cap (rank 245 of 905)
Percentile RankSAB Biotherapeutics, Inc. carries a moderate pipeline score (51/100), with $6.2B risk-adjusted pipeline value, led by High Dose SAB-142 in Type 1 Diabetes (Phase 2), across $75B in total addressable markets.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| High Dose SAB-142 Small molecule | Type 1 Diabetes | Phase 2 | NCT07187531 | 43% | $4.8B | RECRUITING | 159 | VERY_FAST | B (75) | Dec 1, 2028 | LOW_RISK | LOW May 29, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
SAB-142 | Type 1 Diabetes | Phase 2b | 2025-09-22 | |||
SAB-142 | Type 1 Diabetes | Phase 2b | 2025-09-22 | |||
SAB-142 | Type 1 Diabetes | Phase 2b | 2025-09-22 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in SABS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV 104.29 M (32.62%) | Shares Owned 27.23 M (29.5%) | Activity Avg Price $0 |
|---|---|---|---|---|
AFFINITY ASSET ADVISORS, LLC | 0.1 % | 2.20 M | 575.00 K | |
AFFINITY ASSET ADVISORS, LLC | 0.1 % | 2.20 M | 575.00 K | |
AFFINITY ASSET ADVISORS, LLC | 0.1 % | 2.20 M | 575.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
SABS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SABS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SABS
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
SABS Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
SABS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-06-18 | 35 | 0 | 35.00 | 5174 | 0 | 0 | 14.77% | 2.19% | 2.49% | - | - | - |
| 2026-06-18 | 35 | 0 | 35.00 | 5174 | 0 | 0 | 14.77% | 2.19% | 2.49% | - | - | - |
| 2026-06-18 | 35 | 0 | 35.00 | 5174 | 0 | 0 | 14.77% | 2.19% | 2.49% | - | - | - |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| 2.48 | 2 | 48 | 1 | 0.02 | 4 | 4 |
| 2.48 | 2 | 48 | 1 | 0.02 | 4 | 4 |
| 2.48 | 2 | 48 | 1 | 0.02 | 4 | 4 |
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest SAB Biotherapeutics, Inc. (SABS) News & Alerts
-
Demo Biotech Announces Positive Phase 3 Results
Competitive Position
How SABS ranks across every disease it competes in| Indication | Rank | Phase | Best Drug | Top 3 Competitors | Market $B | LoA | Position |
|---|---|---|---|---|---|---|---|
| Genetic Disorders | #3 of 8 | Single Ascending Dose of SAB-176 | TAK RYTM REGN | $7.95B | 0.99 | ||
| Type 1 Diabetes | #8 of 19 | High Dose SAB-142 | LLY NVO SNY | $3.5B | 0.98 |